EOLS Evolus Inc.

-0.49  -3%
Previous Close 14.54
Open 14.77
Price To Book 9.37
Market Cap 385,313,944
Shares 27,424,480
Volume 537,054
Short Ratio
Av. Daily Volume 637,287

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

FDA Approval announced February 1, 2019.
Glabellar lines

Latest News

  1. Evolus Could See Breakout Soon
  2. Evolus, Inc. (EOLS) Q2 2019 Earnings Call Transcript
  3. UPDATE 1-Evolus reports sales of its Botox rival ahead of expectations
  4. Evolus says launch of its Botox rival ahead of its expectations
  5. Evolus Reports Second Quarter 2019 Financial Results
  6. Evolus, Inc. to Host Earnings Call
  7. What's in Store for Flexible Solutions (FSI) in Q2 Earnings?
  8. Barrick (GOLD) to Post Q2 Earnings: What's in the Cards?
  9. Advance Auto Parts (AAP) to Post Q2 Earnings: What's Up?
  10. Evolus to Report Second Quarter 2019 Financial Results and Provide a Business Update on Monday, August 12, 2019
  11. 4 Medical Product Stocks Set to Beat This Earnings Season
  12. Evolus Expands Board of Directors with Appointment of Independent Directors Peter Farrell, Ph.D. and Karah Parschauer, J.D.
  13. Will Evolus Continue to Surge Higher?
  14. Evolus Is Shaping Up Nicely, Time to Go Long
  15. AbbVie (ABBV) Shares Down So Far This Year: Here's Why
  16. Who Has Been Buying Evolus, Inc. (NASDAQ:EOLS) Shares?
  17. If You Had Bought Evolus (NASDAQ:EOLS) Stock A Year Ago, You'd Be Sitting On A 51% Loss, Today
  18. Evolus Could Turn Into an Attractive Play
  19. Allergan Up As Analyst Statement Sparks Business Split Rumors
  20. Allergan Is a $63 Billion Botox Job for AbbVie